SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Roy Glen who wrote (13351)1/15/1998 12:50:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Roy, I expect the retinoids to be used in combination with may drugs and approaches. I can appreciate the molecular combos (i.e. Rexinois with TZD or oter drugs effective in treat type II diabetes) more than combining methedologies, but Panretin is being tested for improvement of immunological parameters in HIV+ patients, and if that data pans out, combination with a vaccine approach may be fruitful.